- Healthcare technology company HEALWELL AI Inc. (TSX:AIDX) has partnered with Sunnybrook Health Sciences Centre
- Through its subsidiary, Pentavere Research Group Inc., HEALWELL intends to demonstrate how Pentavere’s DARWEN AI platform can help improve cancer staging to support treatment decisions and improve patient outcomes
- Published in JAMA Otolaryngology, a leading peer-reviewed medical journal for head and neck cancers, the results found that AI could improve patient care and support oncological decision-making
- HEALWELL AI Inc. last traded at C$1.65 per share
Healthcare technology company HEALWELL AI Inc. (TSX:AIDX) has partnered with Sunnybrook Health Sciences Centre.
Through its subsidiary, Pentavere Research Group Inc., the Toronto-based data science and artificial intelligence (AI) company intends to demonstrate how Pentavere’s DARWEN AI platform can help improve cancer staging to support treatment decisions and improve patient outcomes.
Leading Sunnybrook Health Sciences Centre is Tony Eskander, a globally recognized head and neck surgical oncologist.
“This exciting collaboration with Dr. Eskander and his team shows how Pentavere’s DARWEN AI platform has the ability to support the critical decision-making processes of clinicians ensuring they remain central to patient care and is further proof of our mission to be a leading AI Decision Support for disease detection and preventative care that is supported by peer reviewed validation and partnerships of the highest quality and reputation,” Pentavere’s co-founder and CEO, Aaron Leibtag said in a news release Tuesday. “To our knowledge, this is the first validation of this nature ever published in a peer reviewed publication.”
“Head and neck cancers are incredibly complex to stage, and up to 75 per cent of patients don’t have an accurate stage documented within the first six weeks,” Eskander added. “Pentavere’s AI DARWEN allows clinicians to rapidly make sense of varied clinical documentation buried within the electronic medical record and accurately predict early vs. late-stage cancers. Automating this capability as part of a physician Co-pilot for clinical decision support would be a game changer for cancer treaters and ultimately help improve outcomes for patients.”
Eskander and his team at Sunnybrook Health Sciences Centre sought to evaluate the effectiveness of DARWEN AI in enhancing cancer staging. Published in JAMA Otolaryngology, a peer-reviewed medical journal for head and neck cancers. The results found that AI could improve patient care and support oncological decision-making.
This journal is the first to showcase AI analyzing unstructured clinical text within electronic health records to effectively automate and expedite cancer staging for complex head and neck cancers. This study highlights AI’s potential to improve patient care and oncological decision-making, demonstrating its capability as a clinical decision support tool to assist physicians and enhance outcomes for cancer patients.
Roughly 8,000 Canadians are diagnosed with head and neck cancers each year and over 2,000 will die from it, according to the Canadian Cancer Society. Accurate and timely staging of the cancer can help clinicians to make the best treatment and prognosis decisions, but this often doesn’t happen or is poorly documented. This can directly impact patient outcomes and the ability of the institution to evaluate pathways, quality and survival. It is because of this that clear documentation of cancer stage is a recognized metric of quality cancer care.
HEALWELL AI Inc. is a healthcare technology and data science company focused on preventative care, with a vision to improve healthcare and save lives through early identification and detection of disease. The company leverages AI for patients and doctors to deliver increased access, reduce healthcare costs, and improve patient outcomes.
HEALWELL AI Inc. (TSX:AIDX) last traded at C$1.65 per share.
Join the discussion: Find out what everybody’s saying about this stock on the HEALWELL Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
